Is either citicoline or huperzine A FDA-approved?

No. Citicoline is a US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia. Huperzine A is sold in the US as a dietary supplement with no FDA approval; developed as a drug in China.

Which has stronger human evidence, citicoline or huperzine A?

Neither clearly. Both have human clinical data. The key source for citicoline is ICTUS trial, Lancet 2012; for huperzine A, it is US phase II RCT, Neurology 2011.

What are the main safety concerns with citicoline and huperzine A?

Citicoline is well tolerated, with no safety signal in thousands of patients at high doses. For huperzine A, watch for cholinergic side effects; additive with prescription cholinesterase inhibitors, opposed by anticholinergics, relevant to anesthesia.

Head-to-head

Citicoline vs Huperzine A

Two cholinergic nootropics sold for memory and focus — a choline-donor prescription drug abroad whose largest placebo-controlled trials failed, against a microgram-dosed acetylcholinesterase inhibitor that's pharmacologically a drug wearing a supplement label.

By Julian RothResearch & dataUpdated October 2026

Short answer

Both are supplements with some human trials behind them, so what separates citicoline and huperzine A is the goal. For a reader focused on memory, focus and brain health, citicoline is the relevant choice; huperzine A is marketed for memory, focus and nootropic stacks.

Citicoline

CDP-choline, Cognizin

Clinical data

The best-tested compound on the nootropic shelf, and that is the problem: ICTUS in stroke and COBRIT in brain injury were both null, leaving open-label cognition data and two small manufacturer-linked trials in healthy people.

Full Citicoline evidence review

Huperzine A

Hup A, Huperzia serrata extract

Clinical data

A genuine reversible acetylcholinesterase inhibitor — the same class as donepezil — with mostly low-quality dementia trials behind it, a failed US phase II, no evidence in healthy adults, and a prescription drug's interaction profile sold with none of the oversight.

Full Huperzine A evidence review

Citicoline vs Huperzine A: head to head

FDA status / approved use: Citicoline
US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia
Huperzine A
Sold in the US as a dietary supplement with no FDA approval; developed as a drug in China
Marketed for: Citicoline
Memory, focus, brain health
Huperzine A
Memory, focus, nootropic stacks
Outcome areas: Citicoline
Cognitive function / memory
Huperzine A
Cognitive function / memory
Evidence grade: Citicoline
Clinical data
Huperzine A
Clinical data
How it works: Citicoline
Supplies choline and uridine, which cells use to rebuild CDP-choline for membranes
Huperzine A
Reversible acetylcholinesterase inhibitor, the same class as donepezil
Route and dosing: Citicoline
Oral pill
Huperzine A
Oral capsule in microgram doses, once or twice daily
Headline human result: Citicoline
No benefit in acute ischemic stroke; the 2012 ICTUS trial of 2,298 patients was stopped for futility
Huperzine A
No ADAS-Cog change at 200 µg twice daily in a 210-patient 2011 US phase II Alzheimer's trial
Strongest evidence: Citicoline
ICTUS trial, Lancet 2012Citicoline evidence reviewPubMed 22691567
Huperzine A
US phase II RCT, Neurology 2011Huperzine A evidence reviewPubMed 21502597
Key safety signal: Citicoline
Well tolerated, with no safety signal in thousands of patients at high doses
Huperzine A
Cholinergic side effects; additive with prescription cholinesterase inhibitors, opposed by anticholinergics, relevant to anesthesia
How it is obtained: Citicoline
Over the counter as a dietary supplement
Huperzine A
Over the counter as a dietary supplement

	Citicoline	Huperzine A
FDA status / approved use	US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia	Sold in the US as a dietary supplement with no FDA approval; developed as a drug in China
Marketed for	Memory, focus, brain health	Memory, focus, nootropic stacks
Outcome areas	Cognitive function / memory	Cognitive function / memory
Evidence grade	Clinical data	Clinical data
How it works	Supplies choline and uridine, which cells use to rebuild CDP-choline for membranes	Reversible acetylcholinesterase inhibitor, the same class as donepezil
Route and dosing	Oral pill	Oral capsule in microgram doses, once or twice daily
Headline human result	No benefit in acute ischemic stroke; the 2012 ICTUS trial of 2,298 patients was stopped for futility	No ADAS-Cog change at 200 µg twice daily in a 210-patient 2011 US phase II Alzheimer's trial
Strongest evidence	ICTUS trial, Lancet 2012Citicoline evidence reviewPubMed 22691567	US phase II RCT, Neurology 2011Huperzine A evidence reviewPubMed 21502597
Key safety signal	Well tolerated, with no safety signal in thousands of patients at high doses	Cholinergic side effects; additive with prescription cholinesterase inhibitors, opposed by anticholinergics, relevant to anesthesia
How it is obtained	Over the counter as a dietary supplement	Over the counter as a dietary supplement

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:: Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Citicoline is a prescription neuro-drug in dozens of countries, but its two largest placebo-controlled trials — ICTUS in acute stroke and COBRIT in traumatic brain injury — both failed on their primary endpoints. Huperzine A works by a completely different, more aggressive mechanism: reversible inhibition of acetylcholinesterase, the same drug class as donepezil, dosed in micrograms with a real interaction and side-effect profile most buyers don't realize they're taking on. Neither has convincing evidence in healthy adults seeking a cognitive edge.

Citicoline fits if

You want the gentler mechanism (a choline precursor, not an enzyme inhibitor), accepting its largest trials were negative.

Huperzine A fits if

You understand you're taking a real cholinesterase inhibitor with a prescription drug's interaction profile, not a benign herbal supplement.

Citicoline vs Huperzine A: common questions

Is either citicoline or huperzine A FDA-approved?: No. Citicoline is a US dietary supplement with no FDA approval; prescription medicine in much of Europe, Latin America and Asia. Huperzine A is sold in the US as a dietary supplement with no FDA approval; developed as a drug in China.
Which has stronger human evidence, citicoline or huperzine A?: Neither clearly. Both have human clinical data. The key source for citicoline is ICTUS trial, Lancet 2012; for huperzine A, it is US phase II RCT, Neurology 2011.
What are the main safety concerns with citicoline and huperzine A?: Citicoline is well tolerated, with no safety signal in thousands of patients at high doses. For huperzine A, watch for cholinergic side effects; additive with prescription cholinesterase inhibitors, opposed by anticholinergics, relevant to anesthesia.

Key studies behind each

Citicoline

Wurtman RJ, Regan M, Ulus I, Yu L. (2000). Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. PubMed 10974208
Secades JJ, Gareri P. (2022). Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. PubMed 36544369
Dávalos A, Alvarez-Sabín J, Castillo J, et al. (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. PubMed 22691567
Zafonte RD, Bagiella E, Ansel BM, et al. (2012). Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. PubMed 23168823

Huperzine A

Wang R, Yan H, Tang XC. (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. PubMed 16364207
Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. (2008). Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev. PubMed 18425924
Yang G, Wang Y, Tian J, Liu JP. (2013). Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. PubMed 24086396
Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G. (2002). Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi. PubMed 12181083

The full evidence reviews

Citicoline (CDP-choline): what the evidence actually shows
A prescription neuro-drug in dozens of countries and a supplement in the US — whose two largest, most rigorous trials, in stroke and brain injury, both came back null.
Updated August 2026
Huperzine A: a cholinesterase inhibitor sold as a supplement
Same mechanism as donepezil, opposite regulatory shelf. Three Cochrane reviews, one failed US phase II trial, no evidence in healthy adults — and a real interaction surface most buyers never hear about.
Updated August 2026

Related comparisons

Cerebrolysin vs Citicoline